EDIVOXETINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H26FNO4
Molecular Weight	339.4017
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]1(CNCCO1)[C@@](O)(CC2=CC(F)=CC=C2OC)C3CCOCC3

InChI

InChIKey=CPBHSHYQQLFAPW-ZWKOTPCHSA-N

InChI=1S/C18H26FNO4/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3/t17-,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H26FNO4
Molecular Weight	339.4017
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800026152 | https://www.ncbi.nlm.nih.gov/pubmed/27035159 | https://www.ncbi.nlm.nih.gov/pubmed/28402139 | https://www.ncbi.nlm.nih.gov/pubmed/21511276

Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.	2011 Jun	21511276

Sample Use Guides

In Vivo Use Guide

Open-label study of edivoxetine once daily dosing (0.1-0.3 mg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years. The efficacy, tolerability, and safety of edivoxetine were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose edivoxetine 6-18 mg once daily with placebo for 10 weeks acute therapy followed by 1 year edivoxetine treatment

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:07:17 GMT 2023` Edited by `admin` on `Sat Dec 16 17:07:17 GMT 2023`
Record UNII	3W9N3F4JOO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EDIVOXETINE

Official Name

English

LY-2216684 HYDROCHLORIDE

Code

English

edivoxetine [INN]

Common Name

English

LY-2216684

Code

English

Edivoxetine [WHO-DD]

Common Name

English

(1R)-2-(5-FLUORO-2-METHOXYPHENYL)-1-((2S)-MORPHOLIN-2-YL)-1-(TETRAHYDRO-2H-PYRAN-4- YL)ETHANOL

Systematic Name

English

2-MORPHOLINEMETHANOL, .ALPHA.-((5-FLUORO-2-METHOXYPHENYL)METHYL)-.ALPHA.-(TETRAHYDRO-2H-PYRAN-4-YL)-, (.ALPHA.R,2S)-

Systematic Name

English

EDIVOXETINE [USAN]

Common Name

English

LY2216684

Code

English

Code System Code Type Description

DRUG BANK

DB09184